Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

5.84
-0.1600-2.67%
Post-market: 5.70-0.1400-2.40%17:30 EDT
Volume:35.36K
Turnover:208.67K
Market Cap:2.46M
PE:-0.05
High:6.17
Open:5.89
Low:5.70
Close:6.00
52wk High:3,840.00
52wk Low:5.25
Shares:420.89K
Float Shares:420.71K
Volume Ratio:1.18
T/O Rate:8.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-118.4105
EPS(LYR):-2,427.8177
ROE:-106.98%
ROA:-53.08%
PB:0.19
PE(LYR):0.00

Loading ...

Clearmind Medicine - no Serious Adverse Events Observed in Part a of Cmnd-100 Trial

THOMSON REUTERS
·
Jul 30

Clearmind Announces Positive Safety Findings for Cmnd 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part a of Its FDA-Regulated Clinical Trial

THOMSON REUTERS
·
Jul 30

Clearmind Medicine - All 24 Participants Successfully Complete Treatment in Part a of Cmnd-100 Trial

THOMSON REUTERS
·
Jul 30

Clearmind Medicine completes Part A of CMND-100 trial

TIPRANKS
·
Jul 28

Clearmind Medicine Successfully Completes Part a of Its FDA Regulated Phase I/Ii Trial

Reuters
·
Jul 28

Clearmind Completes Part a Dosing in Phase I/II Cmnd-100 Trial for Alcohol Use Disorder

Reuters
·
Jul 28

Clearmind Targets Hong Kong Patent Protection to Support PTSD Drug Development Push

Reuters
·
Jul 20

Clearmind Medicine - Files Hong Kong Patent Application for Psychedelic Compounds Targeting Ptsd

THOMSON REUTERS
·
Jul 20

Clearmind reports positive retention results for intranasal formulation of MEAI

TIPRANKS
·
Jul 16

Clearmind Medicine Releases Update on Intranasal MEAI Formulation Retention Study

Reuters
·
Jul 16

Clearmind Medicine - Results Validate Clearmind Nasal Drug-delivery Platform for Meai

THOMSON REUTERS
·
Jul 16

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of Its Psychedelic-based Neuroplastogen Meai

THOMSON REUTERS
·
Jul 16

Clearmind Medicine Posts Update on Cmnd-100 First-in-human Trial Webinar Insights

Reuters
·
Jul 13

Clearmind Medicine submits response to HHS request for information

TIPRANKS
·
Jul 10

Clearmind Medicine Responds to the U.S. Administration’s Rfi for Addiction Treatment Innovations as Part of the Great American Recovery Initiative

THOMSON REUTERS
·
Jul 10

Clearmind Reports Successful Formulation Study for Intranasal MEAI Delivery in Alcohol Use Disorder Program

Reuters
·
Jul 08

Clearmind Medicine Issues Press Release Update

Reuters
·
Jul 07

Clearmind Medicine Wins New US Patent for Binge Behavior Regulators

Reuters
·
Jun 29

Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder

Reuters
·
Jun 22

Clearmind Medicine - to Initiate Next Stage of Clinical Program for Alcohol Use Disorder

THOMSON REUTERS
·
Jun 22